Compare HXHX & APM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HXHX | APM |
|---|---|---|
| Founded | 2003 | 2010 |
| Country | China | United Kingdom |
| Employees | 85 | N/A |
| Industry | Trucking Freight/Courier Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.2M | 7.3M |
| IPO Year | N/A | 2018 |
| Metric | HXHX | APM |
|---|---|---|
| Price | $0.86 | $0.86 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 1.5M | 219.0K |
| Earning Date | 05-20-2026 | 03-31-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $1.96 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.33 | $0.65 |
| 52 Week High | $1.84 | $4.47 |
| Indicator | HXHX | APM |
|---|---|---|
| Relative Strength Index (RSI) | 72.66 | 45.60 |
| Support Level | $0.41 | $0.74 |
| Resistance Level | $0.92 | $0.98 |
| Average True Range (ATR) | 0.13 | 0.17 |
| MACD | 0.03 | 0.01 |
| Stochastic Oscillator | 67.90 | 12.59 |
Haoxin Holdings Ltd is engaged in the logistics industry, including container provider of temperature-controlled truckload service and urban delivery services in China, freight forwarding, cold chain transportation and other businesses. The types of goods involved are all kinds of new energy materials that require low temperature, heat preservation, and constant temperature, electronic products, medicines, meat, fruits, vegetables and others.
Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. Aptorum's project pipeline includes SACT-1, a repurposed drug for the treatment of neuroblastoma, and ALS-4, a small molecule for the treatment of bacterial infections caused by Staphylococcus aureus, including but not limited to Methicillin-resistant Staphylococcus aureus (MRSA). Substantially all of the company's revenues are derived from within Hong Kong.